Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2013, Article ID 517239, 6 pages
http://dx.doi.org/10.1155/2013/517239
Research Article

Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer

1Department of Obstetrics and Gynecology, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Ulica Ujejskiego 75, 85-168 Bydgoszcz, Poland
2Department of Laboratory Medicine, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Ulica Jurasza 5, 85-094 Bydgoszcz, Poland

Received 10 May 2013; Revised 28 June 2013; Accepted 5 July 2013

Academic Editor: Kai J. Buhling

Copyright © 2013 Pawel Walentowicz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Park, J.-H. Lee, D. J. Hong, E. Y. Lee, and H.-S. Kim, “Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases,” Clinical Biochemistry, vol. 44, no. 10-11, pp. 884–888, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Walentowicz-Sadlecka, M. Grabiec, P. Sadlecki et al., “Sypniewska G. 25(OH)D3 in patients with ovarian cancer and its correlation with survival,” Clinical Biochemistry, vol. 45, pp. 1568–1572, 2012. View at Publisher · View at Google Scholar
  4. A. La Marca, G. Stabile, A. Carducci Artenisio, and A. Volpe, “Serum anti-Mullerian hormone throughout the human menstrual cycle,” Human Reproduction, vol. 21, no. 12, pp. 3103–3107, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Š. Alebić, N. Stojanović, and M. Zuvić-Butorac, “The IVF outcome counseling based on the model combining DHEAS and age in patients with low AMH prior to the first cycle of GnRH antagonist protocol of ovarian stimulation,” International Journal of Endocrinology, vol. 2013, Article ID 637919, 2013. View at Publisher · View at Google Scholar
  6. R. Rey and N. Josso, “Regulation of testicular anti-Mullerian hormone secretion,” European Journal of Endocrinology, vol. 135, no. 2, pp. 144–152, 1996. View at Google Scholar · View at Scopus
  7. R. R. Behringer, M. J. Finegold, and R. L. Cate, “Müllerian-inhibiting substance function during mammalian sexual development,” Cell, vol. 79, no. 3, pp. 415–425, 1994. View at Google Scholar · View at Scopus
  8. M. M. Lee, P. K. Donahoe, and T. Hasegawa, “Müllerian inhibiting substance in humans: normal levels from infancy to adulthood,” The Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 2, pp. 571–576, 1996. View at Publisher · View at Google Scholar
  9. M. F. Brougham, P. M. Crofton, E. J. Johnson, N. Evans, R. A. Anderson, and W. H. Wallace, “Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, pp. 2059–2067, 2012. View at Publisher · View at Google Scholar
  10. C. L. Cook, Y. Siow, S. Taylor, and M. E. Fallat, “Serum mullerian-inhibiting substance levels during normal menstrual cycles,” Fertility and Sterility, vol. 73, no. 4, pp. 859–861, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Streuli, T. Fraisse, C. Chapron, G. Bijaoui, P. Bischof, and D. de Ziegler, “Clinical uses of anti-Müllerian hormone assays: pitfalls and promises,” Fertility and Sterility, vol. 91, no. 1, pp. 226–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. W. M. Baarends, J. T. J. Uilenbroek, P. Kramer et al., “Anti-Mullerian hormone and anti-Mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth,” Endocrinology, vol. 136, no. 11, pp. 4951–4962, 1995. View at Google Scholar · View at Scopus
  13. J. Shi, Y. Yoshimo, Y. Oshuga et al., “Bone morhogenetic protien-6 stimulates gene expression of follicle stimulating hormone receptor, inhibin/activin β subunit and anti-Müllerian hormone in human granulose cells,” Fertility and Sterility, vol. 92, pp. 1794–1798, 2009. View at Publisher · View at Google Scholar
  14. A. de Vet, J. S. E. Laven, F. H. de Jong, A. P. N. Themmen, and B. C. J. M. Fauser, “Antimüllerian hormone serum levels: a putative marker for ovarian aging,” Fertility and Sterility, vol. 77, no. 2, pp. 357–362, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Fanchin, L. M. Schonäuer, C. Righini, J. Guibourdenche, R. Frydman, and J. Taieb, “Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3,” Human Reproduction, vol. 18, no. 2, pp. 323–327, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. I. A. J. van Rooij, I. den Tonkelaar, F. J. M. Broekmans et al., “Anti-Müllerian hormone is a promising predictor for the occurrence of the menopausal transition,” Menopause, vol. 11, no. 6, pp. 601–606, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. A. La Marca, G. Sighinolfi, D. Radi et al., “Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART),” Human Reproduction Update, vol. 16, no. 2, pp. 113–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Broer, B. W. Mol, M. Dolleman, B. Fauser, and J. M. Broekmans, “The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome,” Current Opinion in Obstetrics and Gynecology, vol. 22, pp. 193–201, 2010. View at Publisher · View at Google Scholar
  19. G. S. Nakhuda, M. C. Chu, J. G. Wang, M. V. Sauer, and R. A. Lobo, “Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization,” Fertility and Sterility, vol. 85, no. 5, pp. 1541–1543, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Lie Fong, P. J. Lugtenburg, I. Schipper et al., “Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies,” Human Reproduction, vol. 23, no. 3, pp. 674–678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Giuseppe, G. Attilio, D. N. Edoardo, G. Loredana, L. Cristina, and L. Vincenzo, “Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD),” Hematology, vol. 12, no. 2, pp. 141–147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Rey, J. C. Sabourin, M. Venara et al., “Anti-Müllerian hormone is specific marker of sertoli -and granulose-cell origin in gonadal tumors,” Human Pathology, vol. 31, pp. 1202–1203, 2000. View at Publisher · View at Google Scholar
  23. M. L. Gustafson, M. M. Lee, R. E. Scully et al., “Müllerian inhibiting substance as a marker for ovarian sex cord tumor,” The New England Journal of Medicine, vol. 326, pp. 1820–1826, 1992. View at Google Scholar
  24. D. B. Seifer, V. L. Baker, and B. Leader, “Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States,” Fertility and Sterility, vol. 95, no. 2, pp. 747–750, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Dubeau, “The cell of origin of ovarian epithelial tumours,” The Lancet Oncology, vol. 9, no. 12, pp. 1191–1197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. P. T. Masiakos, D. T. MacLaughlin, S. Maheswaran et al., “Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS,” Clinical Cancer Research, vol. 5, no. 11, pp. 3488–3499, 1999. View at Google Scholar · View at Scopus
  27. A. E. Stephen, L. A. Pearsall, B. P. Christian, P. K. Donahoe, J. P. Vacanti, and D. T. MacLaughlin, “Highly purified Müllerian inhibiting substance inhibits human ovarian cancer in vivo,” Clinical Cancer Research, vol. 8, no. 8, pp. 2640–2646, 2002. View at Google Scholar · View at Scopus